Develo** new anticancer agents can be useful, with the ability to diagnose and treat
cancer worldwide. Previously, we focused on examining the effects of nonoxidovanadium …

In this work, three titanium (IV)[TiIV (L1–3) 2](1–3) complexes have been reported using
three different tridentate dibasic ONO donor hydrazone ligands, pyridine-4-carboxylic acid (3 …

Diorganotin acylhydrazone complexes with mitochondrial targeting demonstrate significant
potential as replacements for platinum-based complexes due to their potent anticancer …

The idea of coordinating biologically active ligand systems to metal centers to exploit their
synergistic effects has gained momentum. Therefore, in this report, three RuIII complexes 1 …

Four distinct organotin (IV) compounds,[R2Sn (L1)][R= Ph (1) and n-Bu (2)] and [R2Sn
(L2)][R= Ph (3) and n-Bu (4)], have been synthesized from two polydentate proligands such …

The development of active therapeutic agents to treat highly metastatic cancer while
minimizing damage to healthy cells is of utmost importance. Due to potential antioxidant …

Many diorganotin complexes with various alkyl groups exhibit excellent in vitro anticancer
activity. However, most diorganotin is the same alkyl group, and the asymmetric alkyl R …

Six organotin (IV) compounds (1–6) have been synthesized by reaction of the polydentate
pro-ligands H3L and H2L, respectively, with the corresponding diorganotin chlorides. All of …

The exploration of diorganotin (IV) compounds as potential inhibitors of cancer cell growth is
gaining attention. Here, we have emphasized the potential of diorganotin derivatives as …

Three new ONNO-donor tetradentate unsymmetrical salen ligands were synthesized by
using o-phenyl diamine with substituted salicylaldehydes followed by a two-step reaction …